Hypertension and nephrology

[Telmisartan plus amlodipine single-pill combination therapy to achieve blood pressure goal values in hypertensive patients treated by general practitioners – an observational study]

ÁMON Tamás1, BARACSI-BOTOS Viktória1, MÉSZÁROS Ágota2, JÁRAI Zoltán1

FEBRUARY 26, 2022

Hypertension and nephrology - 2022;26(01)

DOI: https://doi.org/10.33668/hn.26.001

[Background: Current European guidelines on the management of hypertension suggests a simple and easily applicable therapeutic strategy to increase effectiveness. Important component of this strategy is the application of single-pill combination (SPC) of RAS inhibitor in combination with calcium antagonists or diuretics as a first step. Primary objective: To assess the percentage of patients reached goal blood pressure ranges after 12 weeks of fix dose combination therapy with telmisartan plus amlodipine according to office blood pressure measurements in hypertensive patients treated by general practitioners (GPs). Patients and methods: After informed consent, 729 patients of 63 GP’s office participated in this multicentre, non-interventional, prospective data collection study. The intention-to-treat (ITT) population was 717, and primary endpoint was analysed in 690 patients (per protocol [PP] population). There were two visits during the study. Blood pressure was measured in all patients at the time of the enrollment and at the second and final visit. Results: The average age of the patients was 62±12 years, 55% of the patients were younger than 65 years, 357 patients (49.8%) of the population was male. The average office blood pressure at baseline was 150±17/88±10 mmHg, and decreased to 130±8.1/78±6.1 mmHg at 12 week (p<0.05). Pulse rate has decreased as well (from 80±9.8 /min to 75±6.3/min). At baseline 10.1% of the patients were at optimal systolic blood pressure goal, 15.8% at optimal diastolic blood pressure goal and only 5.5% simultaneously at systolic and diastolic goal. By the end of the observational period the percentage of patients reached optimal BP goal values increased to 51.6%, 54.1% and 33.0%, respectively (systolic, diastolic, systolic and diastolic). Also the proportion of those who achieved primary target BP below 140/90 mmHg was higher. At baseline 19.2% of patients had BP below 140/90 mmHg, which increased to 87.1% by the end of the study. Patients tolerated SPC telmisartan/amlodipine well, 95% of the patients continued to receive prescribed medication after study conclusion. Conclusion: These real world data shows that the introduction of a fix dose combination therapy after free combination therapy increases the success rate of treatment during a relative short period, however many of the patients would still need higher doses or additional therapy after 3 months in order to achieve the optimal BP target levels. ]


  1. Dél-budai Centrumkórház Szent Imre Egyetemi Oktatókórház, Kardiológiai Profil, Budapest
  2. KRKA Magyarország Kereskedelmi Kft., Budapest



Further articles in this publication

Hypertension and nephrology

[Beyond the blood sugar reduction. SGLT-2 inhibitors in kidney protection]


[Results of cardiovascular safety studies with SGLT-2 inhibitors have shown that in addition to their hypoglycaemic and beneficial cardiovascular effects, they are renoprotective. A number of mechanisms underlying the renoprotective effects of SGLT-2 inhibitors have been shown to reduce albuminuria and deterioration of renal function. Their nephroprotective effects extend over a very wide range of eGFR and albuminuria categories. In the DAPA-CKD study, dapagliflozin was shown to exert its nephroprotective effect regardless of the presence of diabetes and a baseline eGFR, while also having a beneficial effect on cardiovascular endpoints and mortality. Following the confirmation of favourable renal results for SGLT-2 inhibitors, it is no coincidence that they have been included in national and international recommendations for the treatment of chronic kidney disease.]

Hypertension and nephrology

[SARS-CoV-2 fertőzés során kialakult alsó végtagi akut artériás elzáródás esete. „Örülök, hogy élek…”]


Hypertension and nephrology

[Dialysis service in coronavirus pandemic]

SZEGEDI János, HORN Péter, GERGELY László, TÖLGYESI Katalin, MOLNÁR Gergely

[The coronavirus pandemic started at December 2019 from Wuhan. The rate of spread of the coronavirus epidemic has shocked the entire world, and the WHO declared it as a pandemic in March 2020. The first case in Hungary was confirmed in March 2020. The infection primarily damages the lungs but can also infect other organs. The relationship between coronavirus infection and the kidney is bidirectional. On the one hand, the infection can cause acute renal damage, and on the other hand, chronic kidney patients and patients receiving renal replacement therapy are at increased risk of infection due to their immune compromised status. Chronic kidney patients are three times more likely to have a severe Covid-19 infection than the general population. Among patients with severe Covid-19, the incidence of acute renal failure may exceed. Patients treated with the HD program have a higher risk of infection due to transportation and treatment in the common area. The mortality rate of Covid-19 infected patients receiving renal replacement therapy is 20-35% according to international data. Infections occured in all the dialysis centers of the B.Braun Avitum Dialysis Network during both the 2nd and 3rd wave of the epidemic. Epidemiological data confirm that preventive measures are of paramount importance in the field of prevention of infections and in the care of the pandemic. Effective prevention and patient care can only be ensured on the basis of correct epidemiological data. The management of the B.Braun Avitum Dialysis Network decided at the time of the outbreak in Hungary to establish an Operational Staff to perform tasks related to the epidemic. The tasks of the Operational Staff are the following: to ensure an effective, up-to-date connection with the dialysis centers, to update the epidemiological data, and to develop and operate an effective prevention program and action plan. To address the epidemic situation, complex measures were introduced in the Network regulated in a pandemic plan which was periodically reviewed. This document includes detailed hygiene regulations regarding patient transport, screening of dialysis center entrants, proper use of mask and personal protective equipment, hand hygiene, contact and respiratory isolation, rules of behavior, ordering a visitation ban, and regulation of cooperation with the hospital. ]

Hypertension and nephrology

[Dialyzed patients with Covid-19 infection in Hungary in 2020]


[We have observed the number and mortality of dialyzed patients with Covid-19 infection in 2020 in Hungary. We have summarized all of 54 dialysis facility where adult patients were treated. During the year, 1242 cases of infection were confirmed in patients undergoing dialysis. 16% (753/4704) of incident dialysis patients were infected. The number of dialysis patients with all Covid-19 infections was 1995. 31.1% of infected patients have died. The mortality was higher in large hemodialysis centers (patient transport, isolation difficulties, increased risk of contamination). Covid-19 positive patients treated with peritoneal dialysis (PD) had significantly lower mortality than those treated with hemodialysis (HD). Chronic kidney disease (CKD) is the most common risk factor for serious Covid-19 infections worldwide, which is why these patients require increased attention (especially for dialysis and transplant recipients). In 2020, there was no vaccine available in our country]

Hypertension and nephrology

[Metabolic effects of cardiovascular drugs]


[Cardiovascular drugs are used for the treatment and primary and secondary prevention of diseases affecting the cardiovascular system. Like all drugs, these drugs may have pharmacological effects in addition to their therapeutic effects. Of particular importance are the effects that affect, have a positive or negative effect on global or cardiac metabolism. In addition to primary cardiovascular diseases, most cardiovascular diseases are strongly influenced by patient’s metabolic status and adaptation to the disease itself. Drugs that affect global and cardiovascular metabolism, in addition to their recognized main mechanism of action, may be of particular interest, both because of their potential beneficial and detrimental effects, especially in the long run, as these drugs are most likely to be taken by our patients for the rest of their lives. These effects should be known to physicians treating patients with cardiovascular disease, and their therapeutic decisions should be made by this knowledge. This article is intended to assist in this decision making by reviewing the metabolic effects of major cardiovascular drugs.]

All articles in the issue

Related contents

Hypertension and nephrology

[Association between cyclothymic affective temperament and hypertension]


[Affective temperaments (cyclothymic, hypertymic, depressive, anxious, irritable) are stable parts of personality and after adolescent only their minor changes are detectable. Their connections with psychopathology is well-described; depressive temperament plays role in major depression, cyclothymic temperament in bipolar II disorder, while hyperthymic temperament in bipolar I disorder. Moreover, scientific data of the last decade suggest, that affective temperaments are also associated with somatic diseases. Cyclothymic temperament is supposed to have the closest connection with hypertension. The prevalence of hypertension is higher parallel with the presence of dominant cyclothymic affective temperament and in this condition the frequency of cardiovascular complications in hypertensive patients was also described to be higher. In chronic hypertensive patients cyclothymic temperament score is positively associated with systolic blood pressure and in women with the earlier development of hypertension. The background of these associations is probably based on the more prevalent presence of common risk factors (smoking, obesity, alcoholism) with more pronounced cyclothymic temperament. The scientific importance of the research of the associations of personality traits including affective temperaments with somatic disorders can help in the identification of higher risk patient subgroups.]

Lege Artis Medicinae

[Thiazide- or thiazide-like diuretics should be used in the treatment of patients with hypertension? Particularities of the situation in Hungary]


[Diuretics have remained the cornerstone of the antihypertensive treatment since their widespreading in the 1960s. According to the 2018 ESC/ESH Guidelines for the management of arterial hypertension, in the absence of evidence from direct comparator trials and recognizing that many of the approved single-pill combinations are based on hydrochlorothiazide, this drug and thiazide-like indapamide can be considered suitable antihypertensive agents. In the 2018 Hungarian guidelines indapamide is named as the most efficacious diuretic in the treatment of patients with hypertension. The aim of the publication is redefining thiazide- and thiazide-like diuretic use in the treatment of hypertensive patients, with particular attention to presently available hydrochlorothia­zide and indapamide, and their combination drugs in Hungary.]

Lege Artis Medicinae

[Hypertension, COPD and COVID-19. Focus on antihypertensive therapy]


[Chronic obstructive pulmonary disease is a very common comorbidity of hypertension and it is often unrecognised by physicians. The factors involved in the pathomechanism of both diseases should be realised when choosing treatment. Among factors, hypoxia, increased tone of sympathetic nervous system and activation of renin-angiotensin-aldosterone system should primarily be considered. Vascular wall damage and endothelial dysfunction has an important role in both conditions. The goals of treatment are elimination of risk factors, optimizing the blood pressure, the consequential prevention of cardio-cerebrovascular, renal and pulmonary damage; finally prolonging the patients’ life and improving their quality of life as well. Both hypertension and COPD significantly worsen the condition of COVID-19 patients since they increase the severity of the disease and the rate of in-patients’ and their mortality. In the treatment of hypertension among COPD and COVID-19 patients there must be emphasized the medication inhibiting of renin-angiotensin-aldosterone system, such as angiotensin-converting en­zyme inhibitors or angiotensin-II AT1 re­cep­tor antagonists. Special attention concerned the beneficial effect of mineralocorticoid receptor antagonist spironolactone. Other antihypertensive drugs (calcium channel blockers, thiazide-like diu­retics, high selectivity β1 receptor antagonists) may supplement the treatment if necessary. Long-acting β2 receptor agonists, muscarinic receptor antagonists and inhalation corticosteroids may be administered in double or triple combination also in hypertension and COPD as well. It is important to note, that statin therapy and also vitamin D3 improve the condition of COVID-19 patients.]

Hypertension and nephrology

[Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fix combination – a non-interventional trial (RAMONA study)]


[Purpose: Monitoring the effectiveness and safety of the fix combination formulation Egiramlon® therapy containing ramipril and amlodipin in patients, suffering from mild or moderate hypertension despite antihypertensive treatment. Patients and methods: Open, prospective, phase IV clinical observational study, which involved 9169 patients (age >18) with mild or moderate hypertension [TUKEB No: 16927- 1/2012/EKU (294/PI/12.)]. Ramipril/Amlodipin 5/5, 5/10, 10/5, 10/10 mg combinations were administered/ titrated in three visits, during the four months period according to the physician’s decision Blood pressure was measured by validated blood pressure sphygmomanometry and ABPM (Meditech, Hungary). The dosis of the fix combination formulation was determined individually during the visits by the 923 doctors involved in the study. The target blood pressure value was 140/90 mmHg, but in case of high risk patients population (diagnosed cardiovascular disease, diabetes), 130/90 mmHg target value was determined. Results: In 70.1% of the patients had no protocoll deviation. Patients data and examination results were processed according to this 6423 patient population. The average age of the patients were 60.2 year, in 50-50% sex distribution. The average duration of the treated hypertension was 9.8 years and the average blood pressure value was 157/91 mmHg. Till the end of the study, systolic blood pressure has decreased with 26.4 mmHg and diastolic pressure with 11.8 mmHg. An average 5.5 bpm heart rate frequency decreasing was observed at the end of the study. As a result of the treatment 52.4% of the patient population has reached the target blood pressure value.]

Lege Artis Medicinae

[Clinical implication of arterial stiffness in the elderly]


[Hypertension prevalence and cardiovascular risk gradually with age. However this aging process seems to take a more rapid course in some individuals, as reflected in the Early Vascular Aging (EVA) syndrome. Age and high blood pressure are the two main determinants of arterial stiffness which is the core of EVA: the impaired elasticity of the media layer of large elastic arteries (mainly the aorta), a process that can be measured by pulse wave velocity. In elderly hyperten­sives, large arteries stiffen and systolic and pulse pressures increase, due to wave reflections. Arterial stiffness has predictive value for future CV e.g. events, coronary artery dis­ease, stroke, and vascular dementia and even all-cause mortality. The concepts of EVA (Early Vascular Aging) and SUPERNOVA (Super­normal Vascular Aging, the opposite phenotype of EVA) help to understand why early target-organ damages develop in some individuals and why others remain much more “younger” than their chronologic age. New drugs are being developed to treat EVA when lifestyle intervention and conven­tional risk factor controlling drugs are not enough.]